Hudson Edge Investment Partners Inc. Sells 7,998 Shares of Johnson & Johnson $JNJ

Hudson Edge Investment Partners Inc. decreased its position in Johnson & Johnson (NYSE:JNJ) by 18.3% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 35,708 shares of the company’s stock after selling 7,998 shares during the quarter. Johnson & Johnson comprises about 1.3% of Hudson Edge Investment Partners Inc.’s holdings, making the stock its 9th largest position. Hudson Edge Investment Partners Inc.’s holdings in Johnson & Johnson were worth $8,728,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of JNJ. V Square Quantitative Management LLC raised its position in shares of Johnson & Johnson by 4.0% in the first quarter. V Square Quantitative Management LLC now owns 55,896 shares of the company’s stock valued at $13,663,000 after buying an additional 2,142 shares during the last quarter. Beacon Financial Advisory LLC grew its stake in Johnson & Johnson by 4.7% in the 1st quarter. Beacon Financial Advisory LLC now owns 3,394 shares of the company’s stock worth $830,000 after acquiring an additional 152 shares during the period. Evolution Wealth Management Inc. grew its stake in Johnson & Johnson by 17.6% in the 1st quarter. Evolution Wealth Management Inc. now owns 655 shares of the company’s stock worth $160,000 after acquiring an additional 98 shares during the period. WBH Advisory Inc. boosted its holdings in shares of Johnson & Johnson by 0.8% during the first quarter. WBH Advisory Inc. now owns 21,228 shares of the company’s stock worth $5,182,000 after purchasing an additional 160 shares during the last quarter. Finally, QRG Capital Management Inc. grew its position in shares of Johnson & Johnson by 7.3% in the first quarter. QRG Capital Management Inc. now owns 416,978 shares of the company’s stock valued at $101,926,000 after purchasing an additional 28,197 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Investors are buying JNJ ahead of earnings, helped by a higher company outlook, a recent analyst price-target increase, and expectations for another solid quarter. Johnson & Johnson (JNJ) Could Be 34% Below Fair Value Following IMAAVY Update
• Positive Sentiment: Wall Street commentary says JNJ’s recent record run reflects rising price targets and strong institutional buying, reinforcing the bullish view on the stock. Johnson & Johnson (JNJ) Stock Surges Past Record High as Wall Street Raises Price Targets
• Positive Sentiment: Analysts expect J&J to report higher second-quarter earnings, which is helping sentiment into the July 15 earnings release. Johnson & Johnson Likely To Report Higher Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
• Neutral Sentiment: Recent articles continue to frame Johnson & Johnson as a defensive healthcare name with dependable dividend income, which may support holding interest but is not a direct catalyst. Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now
• Negative Sentiment: One market note highlighted unusual put option activity after JNJ’s runup, suggesting some traders are positioning for a pullback or near-term volatility. Unusual Put Option Activity in Johnson & Johnson After JNJ Stock’s Recent Runup

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent analyst reports. Daiwa Securities Group increased their target price on Johnson & Johnson from $237.00 to $246.00 and gave the stock an “outperform” rating in a research report on Thursday, April 16th. Sanford C. Bernstein upped their price objective on shares of Johnson & Johnson from $225.00 to $251.00 and gave the company a “market perform” rating in a research note on Wednesday, April 15th. Argus raised their target price on shares of Johnson & Johnson from $240.00 to $275.00 and gave the stock a “buy” rating in a research report on Thursday, April 16th. Bank of America boosted their target price on shares of Johnson & Johnson from $253.00 to $254.00 and gave the company a “neutral” rating in a report on Wednesday, April 15th. Finally, HSBC set a $290.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Monday. Twenty equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $257.13.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $267.35 on Wednesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77. Johnson & Johnson has a 1-year low of $154.21 and a 1-year high of $269.43. The firm has a market capitalization of $643.56 billion, a P/E ratio of 30.91, a P/E/G ratio of 2.54 and a beta of 0.24. The business’s 50-day simple moving average is $235.09 and its 200-day simple moving average is $232.13.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. The firm had revenue of $24.06 billion during the quarter, compared to the consensus estimate of $23.60 billion. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The company’s revenue was up 9.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Equities analysts predict that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th were issued a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. The ex-dividend date was Tuesday, May 26th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s dividend payout ratio (DPR) is presently 61.97%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of the business’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the transaction, the executive vice president owned 114,288 shares in the company, valued at $27,560,551.20. The trade was a 8.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.